Study Details

Back to Search Results

A Study to Evaluate a Therapeutic Vaccine, ASP0113, in Cytomegalovirus (CMV)-Seropositive Recipients Undergoing Allogeneic, Hematopoietic Cell Transplant (HCT)

This trial is complete
The study has ended normally, and participants are no longer being examined or treated (that is, the last participant's last visit has occurred).

Clinicaltrials.gov ID

The unique identification code given to each clinical study upon registration at ClinicalTrials.gov.
NCT01877655

Astellas Study ID

The unique identification code given by the study sponsor.

0113-CL-1004

EudraCT ID

The unique identification code given to each clinical study upon registration at EudraCT (European Union Drug Regulating Authorities Clinical Trials Database).

2013-000903-18

Follow Trial

Condition

Virus Infections, Stem Cell Transplants

Phase

These clinical trials are done to confirm that an experimental treatment helps participants who have a specific condition. These clinical trials often compare the experimental treatment to another treatment or, if appropriate, a placebo.

Phase 3

Age

18 years - N/A

Sex

Female & Male

Product

ASP0113

Type

A type of clinical study in which participants are assigned to groups that receive one or more intervention/treatment (or no intervention) so that researchers can evaluate the effects of the interventions on biomedical or health-related outcomes.

Interventional

Trial Dates

Sep 2013 - Mar 2022

Masking

Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)

Enrollment number

514

A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial to Evaluate the Protective Efficacy and Safety of a Therapeutic Vaccine, ASP0113, in Cytomegalovirus (CMV)-Seropositive Recipients Undergoing Allogeneic, Hematopoietic Cell Transplant (HCT)

Study summary

Study documents

Study Documents, including study results, are available after a study is completed or terminated, according to Astellas Transparency policy.

Get More Information

Would you like more information about clinical trial sites that are recruiting participants for A Study to Evaluate a Therapeutic Vaccine, ASP0113, in Cytomegalovirus (CMV)-Seropositive Recipients Undergoing Allogeneic, Hematopoietic Cell Transplant (HCT)? Contact us by filling our your information to the right and we’ll respond to you.

By clicking ["Continue/Submit"], you agree that Astellas may contact you by email with information to help you connect with clinical trial sites. While we can connect you to clinical trial sites, we cannot answer questions about any investigational therapy through email. Your consent to receiving emails is not a requirement to participate in a clinical trial or study. For more information, including how to unsubscribe at any time, see our Privacy Notice & Cookies Policy.

Locations

Site JP81001

Fukuoka, Japan

Site US10036

Rochester, United States, 55905

Site US10024

Seattle, United States, 98109

Site JP81003

Nagoya, Japan

Site DE49003

Wiesbaden, Germany, 65191

Site US10029

Winston-Salem, United States, 27157

Site US10025

Chapel Hill, United States, 27514

Site JP81005

Fukuoka, Japan

Site KR82004

Seoul, Republic of Korea, 06351

Site FR33010

Nice, France, 06200

Site US10039

Seattle, United States, 98108

Site KR82003

Seoul, Republic of Korea, 110744

Site BE32005

Leuven, Belgium, 3000

Site JP81009

Minato-ku, Japan

Site US10028

Birmingham, United States, 35294

Site DE49008

Tuebingen, Germany, 72076

Site KR82001

Seoul, Republic of Korea, 137-701

Site ES34003

Granada, Spain, 18012

Site US10046

Salt Lake City, United States, 84143

Site US10031

Richmond, United States, 23298

Site ES34012

Barcelona, Spain, 08036

Site DE49007

Muenster, Germany, 48149

Site DE49014

Koln, Germany, 50937

Site JP81007

Sapporo, Japan

Site TW88602

Taipei City, Taiwan, Province of China, 11217

Site DE49001

Wurzburg, Germany, 97080

Site US10016

Nashville, United States, 37232

Site US10002

Dallas, United States, 75246

Site CA15001

Vancouver, Canada, V5Z 1M9

Site US10009

Houston, United States, 77030

Site US10042

St. Louis, United States, 63110

Site US10010

Louisville, United States, 40202

Site US10033

Portland, United States, 97239

Site US10019

Milwaukee, United States, 53226

Site US10030

Tampa, United States, 33612

Site US10012

Atlanta, United States, 30322

Site DE49004

Jena, Germany, 07740

Site FR33004

Paris, France, 75010

Site US10037

Chicago, United States, 60637

Site US10027

Rochester, United States, 14642

Site DE49012

Dusseldorf, Germany, 40225

Site US10045

Houston, United States, 77030

Site AU43001

Herston, Australia, QLD 4029

Site BE32006

Gent, Belgium, 9000

Site US10007

Indianapolis, United States, 46237

Site US10020

Westwood, United States, 66205

Site ES34004

Barcelona, Spain, 08908

Site FR33011

Besancon, France, 25030

Site US10011

Baltimore, United States, 21205

Site CA15004

Montreal, Canada, H2W 1S6

Site US10043

Baltimore, United States, 21201

Site CA15003

Quebec, Canada, G1R 2J6

Site JP81011

Maebashi, Japan

Site AU43002

Melbourne, Australia, VIC 3004

Site DE49015

Mainz, Germany, 55131

Site FR33009

Nantes, France, 44093

Site ES34011

Madrid, Spain, 28028

Site US10047

New York, United States, 10032

Site US10040

Chicago, United States, 60611

Site SE46001

Gothenburg, Sweden, 413 45

Site AU43004

Adelaide, Australia, SA 5000

Site ES34010

Salamanca, Spain, 37007

Site FR33005

Creteil, France, 94000

Site DE49002

Leipzig, Germany, 04103

Site US10026

Stanford, United States, 94305

Site ES34007

Murcia, Spain, 30008

Site DE49010

Bonn, Germany, 53127

Site TW88601

Taipei City, Taiwan, Province of China, 10002

Site ES34006

Barcelona, Spain, 08041

Site SE46004

Lund, Sweden, 221 85

Site SE46005

UMEA, Sweden, 901 85

Site BE32007

Roeselare, Belgium, 8800

Site SE46006

Linkoping, Sweden, 581 85

Site US10044

Tucson, United States, 85724

Site ES34009

Valencia, Spain, 46010

Site ES34001

Badalona, Spain, 08615

Site DE49006

Ulm, Germany, 89081

Site CA15002

Toronto, Canada, M5G 2M9

Site ES34005

Cordoba, Spain, 14004

Site TW88603

Taoyuan County, Taiwan, Province of China, 33305

Site JP81004

Shinjuku-ku, Japan

Site US10013

Chicago, United States, 60612

Site US10021

Boston, United States, 02114

Site ES34002

Santander, Spain, 39008

Site JP81010

Bunkyo-ku, Japan

Site DE49013

Gottingen, Germany, 37075

Site SE46003

Stockholm, Sweden, 14186

Site AU43003

Parkville, Australia, VIC, 3050

Site DE49005

Stuttgart, Germany, 70376

Site US10035

San Francisco, United States, 94143

Site JP81006

Osaka, Japan

Site JP81008

Chuo-ku, Japan

Site BE32001

Brugge, Belgium, 8000

Site US10023

Hackensack, United States, 07601-2105

Site KR82002

Seoul, Republic of Korea, 05505

The purpose of this website is to offer education and information to patients and their families and friends, the public, and healthcare professionals about the clinical trial process. In addition, the website will provide specific information about Astellas clinical trials. Please read the complete Astellas Transparency Policy to learn about the clinical trial information available on this website

© ASTELLAS PHARMA GLOBAL DEVELOPMENT, INC.

POWERED BY:

Pharma Intelligence logo